New Approaches Seek to Meet the Challenge of Graft-Vs-Host Disease
April 28th 2021The curative potential of allogeneic hematopoietic stem cell transplantation for many hematologic malignancies is hindered by the frequent development of graft-vs-host disease, a potentially fatal complication resulting from a complex interaction between donor immune cells in the graft and the host’s immune system.
Landscape for Unresectable HCC Comes Into Sharper Focus
April 27th 2021After years of stagnation, the paradigm for treating patients with unresectable intermediate-stage or advanced hepatocellular carcinoma is starting to change as a result of novel strategies and evolving views of appropriate patient populations for systemic therapies.
Phase 1/2 Studies Set the Stage for Targeted Combos in B-Cell Lymphomas
April 27th 2021Although chemotherapy is not likely to lose its place in the frontline treatment of patients with B-cell lymphomas, encouraging data from early-phase studies evaluating the use of targeted agents in combination with and without chemotherapy are capturing the interest of investigators in the field.
Apalutamide Maintains OS Benefit in Castration-Sensitive Prostate Cancer
April 26th 2021Apalutamide plus androgen deprivation therapy maintained an overall survival advantage over placebo for a broad population of patients with metastatic castration-sensitive prostate cancer after nearly 4 years of median follow-up.
A Desire to Be a Healer Drives Breast Cancer Expert Forward
April 23rd 2021Sara A. Hurvitz, MD, can remember the exact moment she decided to become an oncologist. It was her first day at the University of Southern California School of Medicine, which she had entered in 1995 without a firm idea of what discipline she wanted to pursue.
Tucatinib Combo Has Potential as Second-Line Option in HER2+ Gastric/GEJ Cancers
April 20th 2021Investigators are exploring a dual HER2-targeting strategy that incorporates tucatinib into a novel combination as second-line therapy for patients with HER2-positive gastric and esophageal cancers.
Clinical Progress Creates Need for Decision-Support Tools
April 20th 2021The current endorsement of 3 COVID-19 vaccines in the United States, with several additional products pending FDA review, in less than 1 year from the identification of the structure of the COVID-19 virus is simply remarkable.